公开(公告)号：EP3875605A1

公开(公告)日：2021-09-08

申请号：EP21155139.5

申请日：2016-05-09

申请人： Agency for Science, Technology and Research ,  National University Hospital (Singapore) Pte Ltd ,  National University of Singapore

发明人： ZOU, Ruiyang ,  ZHOU, Lihan ,  TOO, Heng-Phon ,  RICHARDS, Arthur Mark ,  WONG, Lee Lee ,  LAM, Su Ping Carolyn

IPC分类号： C12Q1/6883

摘要： Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subject and wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining an altered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.

公开(公告)号：EP4417706A2

公开(公告)日：2024-08-21

申请号：EP24166785.6

申请日：2016-05-09

申请人： Agency for Science, Technology and Research ,  National University Hospital (Singapore) Pte Ltd ,  National University of Singapore

发明人： ZOU, Ruiyang ,  ZHOU, Lihan ,  TOO, Heng-Phon ,  RICHARDS, Arthur Mark ,  WONG, Lee Lee ,  LAM, Su Ping Carolyn

IPC分类号： C12Q1/6883

CPC分类号： C12Q2600/17820130101 ,  C12Q2600/15820130101 ,  C12Q1/6883

摘要： Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subject and wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining an altered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.